Sep 2026· British Journal of Clinical Pharmacology· 0 citations· 18 references
Medicine
TL;DR
Pharmacogenomically implicated medication prescriptions are common in Singapore and are particularly prevalent in elderly populations, with males prescribed these medications earlier in life than females and Indians and Malays were more likely to be prescribed these medicines at a younger age than Chinese.
Abstract
Aim
To assess the potential impact of implementing pre-emptive pharmacogenomic (PGx) testing in Singapore, focusing on prevalence and genetic actionability of PGx prescriptions.
Methods
Electronic Health Records from 2014 to 2021 were obtained from the National University Hospital (NUH), a tertiary medical centre serving approximately 6% of Singapore's population, which were filtered for pharmacogenomically implicated medicines (CPIC Level A or A/B), defined as PGx medications. Coupling this with published data of whole-genome sequencing of 9051 Singaporeans, we estimated the proportion of patients whose prescriptions might have been modified based on pre-emptive PGx at population level.
Results
From 2014 to 2021, a total of 1 157 359 unique patients were seen at NUH, with 38.1% to 43.0% of patients with prescriptions receiving at least one PGx medication annually, exhibiting minimal variance over year of prescription, sex or race/ethnicity. The most frequently prescribed PGx medications were omeprazole, statins and tramadol, while the most implicated pharmacogenes were CYP2C19, CYP2D6 and SLCO1B1. The age-dependent increase in PGx medication exposure varied significantly by sex, with males prescribed these medications earlier in life than females. Similarly, Indians and Malays were more likely to be prescribed these medicines at a younger age than Chinese. Based on frequency of PGx variants in Singaporeans, we estimate that 18.4% of patients could have their prescriptions modified from pre-emptive PGx testing.
Discussion
Pharmacogenomically implicated medication prescriptions are common in Singapore and are particularly prevalent in elderly populations. Strategic investments in infrastructure and policy development will be pivotal to the successful integration of pre-emptive PGx into clinical practice.
Pharmacogenomics (PGx) is a key component of precision medicine, linking genetic variation to drug response, effectiveness, and toxicity. However, Middle Eastern and North African (MENA) populations remain underrepresented in global genomic databases, limiting PGx’s clinical utility in these regions. This review examin...
Abderraouf Haitamar, Shahid Eiyad Abu-Nada, Mariam Wed Eladham et al.· Frontiers in Pharmacology· 0 citations
It is demonstrated that PGx testing may decrease polypharmacy, which may also reduce not only the number of drug–drug interactions, but also the cost to healthcare systems and patients.
A. Halaris· International Journal of Neu...· 0 citations
Recent advances in pharmacogenomic guidelines, regulatory labelling, and clinical implementation are supporting broader adoption of pharmacogenetic testing. We analysed whole-genome sequencing data from 3,205 participants in the Medical Genome Reference Bank, a healthy older Australian reference cohort predominantly of...
Kosar Hooshmand, Stephen Hughes, S. Stocker et al.· Frontiers in Pharmacology· 0 citations
This work drafts a comprehensive assessment using a comprehensive assessment including diagnosis, treatment and medication history, comorbid conditions and individual PGx profiles for patients who experienced inadequate treatment response or pronounced side effects from psychotropic medications, and discusses guideline...
R. van Westrhenen· International Journal of Neu...· 0 citations
A precision medicine strategy is likely to be more impactful, when pharmacogenomics (PGx) guided selection of drugs and dosage wherever applicable is implemented across the globe. In regions where resources are disproportionately distributed, PGx implementation in routine clinical care can play a critical role in ensur...
Mohamad Nagy, G. M. Raj, R. Priyadarshini et al.· Pharmacogenomics (London)· 0 citations
Co-occurrence was concentrated in a few widely dispensed classes, principally proton-pump inhibitors and antidepressants acting through CYP2C19 and statins through SLCO1B1.
C. Rentsch, K. Bhaskaran, M. Pavičić et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.